Mizuho analyst Irina Koffler expects positive momentum in shares of Pacira Pharmaceuticals after Exparel has been recommended for more favorable outpatient reimbursement in Ambulatory Surgical Centers in 2019. Centers for Medicare & Medicaid Services proposed an average selling price plus 6% reimbursement for Exparel in outpatient facilities for 2019, Koffler tells investors in a research note. She keeps a Neutral rating on Pacira with a $33 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.